Your browser doesn't support javascript.
loading
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Zhang, Deyi; Harris, Hailey M; Chen, Jonathan; Judy, Jen; James, Gabriella; Kelly, Aileen; McIntosh, Joel; Tenn-McClellan, Austin; Ambing, Eileen; Tan, Ying Siow; Lu, Hao; Gajewski, Stefan; Clifton, Matthew C; Yung, Stephanie; Robbins, Daniel W; Pirooznia, Mehdi; Skånland, Sigrid S; Gaglione, Erika; Mhibik, Maissa; Underbayev, Chingiz; Ahn, Inhye E; Sun, Clare; Herman, Sarah E M; Noviski, Mark; Wiestner, Adrian.
Afiliación
  • Zhang D; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Harris HM; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Chen J; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Judy J; Bioinformatics Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • James G; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Kelly A; Nurix Therapeutics, Inc, San Francisco, CA.
  • McIntosh J; Nurix Therapeutics, Inc, San Francisco, CA.
  • Tenn-McClellan A; Nurix Therapeutics, Inc, San Francisco, CA.
  • Ambing E; Nurix Therapeutics, Inc, San Francisco, CA.
  • Tan YS; Nurix Therapeutics, Inc, San Francisco, CA.
  • Lu H; Nurix Therapeutics, Inc, San Francisco, CA.
  • Gajewski S; Nurix Therapeutics, Inc, San Francisco, CA.
  • Clifton MC; Nurix Therapeutics, Inc, San Francisco, CA.
  • Yung S; Nurix Therapeutics, Inc, San Francisco, CA.
  • Robbins DW; Nurix Therapeutics, Inc, San Francisco, CA.
  • Pirooznia M; Bioinformatics Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Skånland SS; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Gaglione E; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Mhibik M; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Underbayev C; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Ahn IE; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Sun C; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Herman SEM; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Noviski M; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Wiestner A; Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Blood ; 141(13): 1584-1596, 2023 03 30.
Article en En | MEDLINE | ID: mdl-36375120
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Moldova
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Moldova